Abstract: Respiratory syncytial virus （RSV） is the most important viral pathogen causing acute lower respiratory tract infections in children under 5 years of age and poses a serious threat to infant health. After more than 60 years， the development of RSV vaccines and monoclonal antibodies has been moving forward amid bumps. Recently， several RSV vaccines and monoclonal antibodies have entered phase Ш clinical trials， which brings light to the prevention of RSV. We reviewed the new progress in research and prevention of RSV， so as to provide help for the prevention and control of RSV.